• Alvotech filed a European Medicines Agency application for AVT29, a proposed biosimilar to Eylea 8 mg (Eylea HD).
• Submission was made as a line extension to the existing European marketing authorization for Mynzepli, its Eylea 2 mg biosimilar.
• Partner Advanz Pharma will handle registration, commercialization in Europe under the companies’ agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140430PRIMZONEFULLFEED1001277829) on October 14, 2026, and is solely responsible for the information contained therein.